Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R T Silver

Showing results (121-130 of 139) with videos related to

Pageof 14
Sort By:
Health Psychology : Official Journal of the Division of Health Psychology, American Psychological Association|February 24, 2001
Persistent symptoms among survivors of Hodgkin's disease: an explanatory model based on classical conditioningC L Cameron, D Cella, J E Herndon, et al.
Cancer|January 15, 1980
Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group BN I Nissen, T F Pajak, L A Leone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1996
Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B studyM Perloff, L Norton, A H Korzun, et al.
Leukemia|February 9, 2016
Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or bothS Koschmieder, T I Mughal, H C Hasselbalch, et al.
Nouvelle Revue Francaise D'Hematologie|January 1, 1981
Resistance to therapy of acute leukemia developing in the course of polycythemia veraP B Donovan, S A Landaw, C Dresch, et al.
The Cancer Journal From Scientific American|November 1, 1995
Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapyD H Henry, B J Brooks, D C Case, et al.
Blood Cancer Journal|March 9, 2013
Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH SymposiumA Tefferi, O Abdel-Wahab, F Cervantes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 1998
Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group BA B Kornblith, J E Herndon, E Zuckerman, et al.
Cancer|August 15, 1980
A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's diseaseM R Cooper, T F Pajak, N I Nissen, et al.
Leukemia|April 11, 2008
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinibA Hochhaus, M Baccarani, M Deininger, et al.
Pageof 14

Showing results (121-130 of 139) with videos related to

Sort By:
Pageof 14
Health Psychology : Official Journal of the Division of Health Psychology, American Psychological Association|February 24, 2001
Persistent symptoms among survivors of Hodgkin's disease: an explanatory model based on classical conditioningC L Cameron, D Cella, J E Herndon, et al.
Cancer|January 15, 1980
Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group BN I Nissen, T F Pajak, L A Leone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1996
Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B studyM Perloff, L Norton, A H Korzun, et al.
Leukemia|February 9, 2016
Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or bothS Koschmieder, T I Mughal, H C Hasselbalch, et al.
Nouvelle Revue Francaise D'Hematologie|January 1, 1981
Resistance to therapy of acute leukemia developing in the course of polycythemia veraP B Donovan, S A Landaw, C Dresch, et al.
The Cancer Journal From Scientific American|November 1, 1995
Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapyD H Henry, B J Brooks, D C Case, et al.
Blood Cancer Journal|March 9, 2013
Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH SymposiumA Tefferi, O Abdel-Wahab, F Cervantes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 1998
Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group BA B Kornblith, J E Herndon, E Zuckerman, et al.
Cancer|August 15, 1980
A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's diseaseM R Cooper, T F Pajak, N I Nissen, et al.
Leukemia|April 11, 2008
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinibA Hochhaus, M Baccarani, M Deininger, et al.
Pageof 14